This Month in JNM

May 1, 2018

Hot Topics – 131I controversies and lessons: Tulchinsky and colleagues present a review and critique of a recent article on the risks of secondary hematologic malignancy with radioactive iodine treatment and identify related lessons to be learned. Page 723

The State of the Art – PET and cancer drug development: Waaijer and colleagues focus on current applications of PET molecular imaging in the development of small molecules, antibodies, and antihormonal anticancer drugs. Page 726

Continuing Education – 18F-fluciclovine PET and prostate cancer: Parent and Schuster provide an educational overview of 18F-fluciclovine PET in primary and metastatic prostate cancer, including imaging procedures and interpretation, as well as comparisons with conventional imaging and other agents. Page 733

Focus on Molecular Imaging – Advanced ultrasound imaging and therapy: Rix and colleagues offer a review of recent developments in diagnostic and therapeutic ultrasound, highlighting multiple innovation tracks and their translational potential. Page 740

Editorial – Salivary gland toxicity after PSMA therapy: Taïeb and colleagues offer perspective on current understanding of posttreatment toxicity in prostate-specific membrane antigen (PSMA)–targeted radionuclide therapy, with a focus on xerostomia and the need for stratification of toxicity risk. Page 747

18F-FDG–avid thyroid incidentalomas: Pattison and colleagues investigate overall and thyroid cancer–specific survival in patients with 18F-FDG–avid thyroid incidentalomas, assessing long-term follow-up to evaluate the validity of American Thyroid Association recommendations on fine-needle aspiration cytology. Page 749

PET/CT, MTC, and vandetanib: Werner and colleagues explore the role of metabolic imaging with 18F-FDG PET/CT shortly before and 3 months after initiation of tyrosine kinase inhibitor treatment in patients with advanced medullary thyroid carcinoma. Page 756

18F-fluciclovine PET/MR for prostate cancer: Elschot and colleagues determine whether quantitative imaging features derived from combined 18F-fluciclovine PET/multiparametric MR imaging show potential for detection and characterization of primary prostate cancer. Page 762

Prediction of radioembolization outcome: Ingrisch and colleagues explore the feasibility of predicting outcomes from 90Y radioembolization in patients with intrahepatic tumors, using pretherapeutic baseline parameters and a machine-learning approach based on random survival forests. Page 769

PET/CT in Erdheim–Chester disease: Young and colleagues assess the utility of 18F-FDG PET/CT for diagnosis, management, and treatment of Erdheim–Chester disease, including potential as an imaging biomarker for the presence of a BRAF mutation. Page 774

DLC-induced iodide uptake in ATC: Tesselaar and colleagues research the effects of autophagy-activating digitalislike compounds on differentiation and proliferation of anaplastic thyroid cancer cell lines as a potential approach to restore iodide avidity in this rare thyroid cancer. Page 780

Invited Perspective – Choosing tracers in prostate cancer: Rowe and colleagues provide perspective on the importance and challenges of choosing the right PET radiotracer for prostate cancer and preview an article in this issue of JNM comparing 2 widely studied agents. Page 787

68Ga-PSMA-11 and 18F-fluciclovine PET/CT: Calais and colleagues compare PET/CT detection rates in localizing recurrent disease using 68Ga-labeled prostate-specific membrane antigen–11 and 18F-fluciclovine. Page 789

Duration of 225Ac-PSMA tumor control: Kratochwil and colleagues report on parameters for and first indicators of efficacy in 225Ac-labeled prostate-specific membrane antigen–617 therapy in a group of patients with metastatic castration-resistant prostate cancer. Page 795

68Ga-RM2 PET/MR in prostate cancer: Minamimoto and colleagues describe imaging findings with this synthetic bombesin receptor antagonist, which targets gastrin-releasing peptide receptor, in patients with biochemical recurrence of prostate cancer and negative conventional imaging. Page 803

FEATURED ARTICLE OF THE MONTH177Lu-3BP-227 pancreatic cancer therapy: Baum and colleagues report on salvage radiopharmaceutical therapy with this novel neurotensin receptor 1 antagonist in patients with ductal pancreatic adenocarcinoma. Page 809

Synthesis and evaluation of FIBG: Yamaguchi and colleagues detail a 2-step radiosynthetic method to obtain 18F-FIBG and evaluate the diagnostic and therapeutic potential of 18F-FIBG and 131I-FIBG in a pheochromocytoma model. Page 815

Spatiotemporal accumulation of Ab in AD: Whittington and colleagues apply mathematic modeling to b-amyloid accumulation in in vivo PET imaging data to investigate competing theories of Ab spread in Alzheimer disease. Page 822

18F-FDS in rat models of renal disorders: Werner and colleagues investigate the potential of 18F-FDS PET as a more precise functional renal imaging agent using rat models of kidney disease. Page 828

Sexual dimorphism in preclinical imaging: Chan and colleagues explore the question of whether sex influences quantitative imaging metrics based on 18F-FLT uptake and tissue distribution in mouse models of cancer. Page 833

FEATURED BASIC SCIENCE ARTICLEMacrophage imaging in arthritis: Chung and colleagues evaluate the results of 18F-FEDAC PET imaging in a murine model of rheumatoid arthritis, including visualization of active inflammation sites in arthritic joints. Page 839

MR-compatible mobile PET scanner: Nakamoto and colleagues report on image quality, lesion detection rate, quantitative values, and registration accuracy of a flexible PET scanner prototype that facilitates fused PET and MR imaging. Page 846

ZeDD CT for pelvic PET/MR: Leynes and colleagues propose the use of patient-specific multiparametric MR imaging consisting of Dixon MR imaging and proton-density–weighted zero-echo-time MR to directly synthesize pseudo-CT images. Page 852